Could Adult European Pharmacoresistant Epilepsy Patients Be Treated With Higher Doses of Zonisamide?

Abstract

High doses of ZNS are effective and safe in pharmacoresistant epileptic patients. Therapeutic drug monitoring of ZNS may be considered at therapeutic failure.

Evaluation of Safety in Exceeding Maximum Adult Doses of Commonly Used Second-Generation Antiepileptic Drugs in Pediatric Patients

“…A study in adults examined whether large dosages of ZNS (defined as >500 mg/day) were safe and effective in pharmacoresistant epilepsy. 12 A total of 9 patients received a mean dosage of 633 mg/day, and this was found to be efficacious (>50% reduction rate of seizures) in 55% of those patients. Adverse events were seen in 3 (37%) and included anorexia, weight loss, and somnolence.…”